No Data
Shen Zhen Weiguang Biological Products (002880.SZ) will distribute a dividend of 2 yuan per share for the year 2023.
Shenzhen Weiguang Biological Products (002880.SZ) announced that the 2023 annual equity distribution plan is based on the company’s total existing share capital of 226,800,000 shares, paying a cash dividend of 2.00 yuan per 10 shares to all shareholders. The equity distribution stock registration date is July 11, 2024; ex-dividend and ex-right dates are July 12, 2024.
Shen Zhen Weiguang Biological Products (002880.SZ): Completion of the third phase of employee stock purchase plan.
Weiguang Biological Products (002880.SZ) announced on July 4th that as of July 3, 2024, the third phase of employee stock ownership plan had accumulated a total of 787,000 shares of company stocks purchased through the secondary market, accounting for 0.35% of the total share capital of the company. The average transaction price was around 28.89 yuan/share, with a transaction amount of 22.7364 million yuan. The purchase of company stocks under this employee stock ownership plan has been completed. The locking period of the company's stocks purchased under this employee stock ownership plan will be 12 months from the date of the last transfer of the stocks announced by the company, which is from July 5, 2024 to July 4, 2025.
Shen Zhen Weiguang Biological Products (002880.SZ): The third phase of employee stock ownership plan has accumulated the purchase of 0.25% of the shares.
On June 20th, Gelonhui reported that Shen Zhen Weiguang Biological Products (002880.SZ) announced that as of June 20, 2024, the third phase of the employee stock ownership plan purchased a total of 567,700 shares of the company's stock through secondary market bidding, accounting for 0.25% of the total share capital of the company, with a transaction amount of approximately 16.6 million yuan and an average transaction price of approximately 29.24 yuan/share.
Shenzhen Weiguang Biological Products (002880.SZ): The human coagulation factor VIII has been launched and sold in the first quarter of this year.
On June 13th, Gelunhui reported that an investor asked Weiguang Biological Products (002880.SZ) on the investor interaction platform, "Has the company started selling human coagulation factor VIII? What is the expected sales volume for this year?" The company replied that human coagulation factor VIII was launched for sale in the first quarter of this year, and the company will continue to increase market development efforts, solidly do a good job in customer service, continuously enhance customer stickiness, and strive to improve operational performance.
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.
Weiguang Biological Products Gets Nod for Human Prothrombin Complex
Some Shareholders Feeling Restless Over Shenzhen Weiguang Biological Products Co., Ltd.'s (SZSE:002880) P/E RatioNo Data
